These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24490745)

  • 1. Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus.
    Weidman-Evans E; Metz SM; Evans JD
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):225-33. PubMed ID: 24490745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin: a multitasking medication.
    Bailey CJ
    Diab Vasc Dis Res; 2008 Sep; 5(3):156. PubMed ID: 18777487
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
    Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
    J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
    Ametov AS; P'ianykh OP; Chernikova NA
    Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intensive blood glucose lowering to reduce cardiovascular risk: contra].
    Marx N
    Dtsch Med Wochenschr; 2009 May; 134(20):1061. PubMed ID: 19421930
    [No Abstract]   [Full Text] [Related]  

  • 8. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intensive blood glucose lowering to reduce cardiovascular risk: pro].
    Martin S
    Dtsch Med Wochenschr; 2009 May; 134(20):1060. PubMed ID: 19421929
    [No Abstract]   [Full Text] [Related]  

  • 10. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.
    Bergenstal RM; Bailey CJ; Kendall DM
    Am J Med; 2010 Apr; 123(4):374.e 9 -18. PubMed ID: 20362759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic management of the patient with type 2 diabetes.
    Quinn L
    Nurs Clin North Am; 2001 Jun; 36(2):217-42, vi. PubMed ID: 11382561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.
    Green JB
    Postgrad Med; 2014 May; 126(3):190-204. PubMed ID: 24918803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of antidiabetes medications: An update.
    Bailey CJ
    Clin Pharmacol Ther; 2015 Aug; 98(2):185-95. PubMed ID: 25820533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?
    Rensing KL; Reuwer AQ; Arsenault BJ; von der Thüsen JH; Hoekstra JB; Kastelein JJ; Twickler TB
    Diabetes Obes Metab; 2011 Dec; 13(12):1073-87. PubMed ID: 21736687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What have we learned about the treatment of type 2 diabetes? The evolving paradigms.
    Freeman JS; Horton ES
    Am J Ther; 2012 Nov; 19(6):449-64. PubMed ID: 23154228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergency management of oral hypoglycemic drug toxicity.
    Rowden AK; Fasano CJ
    Emerg Med Clin North Am; 2007 May; 25(2):347-56; abstract viii. PubMed ID: 17482024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the cardiovascular safety of diabetes therapies.
    Goldfine AB
    N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
    [No Abstract]   [Full Text] [Related]  

  • 20. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
    Parks M; Rosebraugh C
    N Engl J Med; 2010 Mar; 362(9):774-7. PubMed ID: 20164475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.